Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
Erdem Çubukçu, Kaan Helvacı, Hakan Harputluoğlu, Fatih Selçukbırıcık et autres